Results 31 to 40 of about 9,676 (179)

Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT While earlier therapeutic strategies for the treatment of hepatitis C virus (HCV) infection relied exclusively on interferon (IFN) and ribavirin (RBV), four direct-acting antiviral agents (DAAs) have now been approved, aiming for an interferon-free strategy with a short treatment duration and fewer side effects.
Dandan, Liu, Juan, Ji, Tanya P, Ndongwe, Eleftherios, Michailidis, Charles M, Rice, Robert, Ralston, Stefan G, Sarafianos   +6 more
openaire   +2 more sources

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052 [PDF]

Journal of Virology, 2011
ABSTRACT BMS-790052, targeting nonstructural protein 5A (NS5A), is the most potent hepatitis C virus (HCV) inhibitor described to date. It is highly effective against genotype 1 replicons and also displays robust genotype 1 anti-HCV activity in the clinic (M. Gao et al., Nature 465:96-100, 2010).
Robert A, Fridell, Dike, Qiu, Lourdes, Valera, Chunfu, Wang, Ronald E, Rose, Min, Gao   +5 more
openaire   +2 more sources

Analysis of genetic polymorphisms and drug resistance mutations in the NS5 region of HCV genome (Flasuviricetes: Amarillovirales: Flaviviridae: Hepacivirus C) in samples obtained in 2022–2023 from HIV-infected treatment-naive residents of Altai Krai

Вопросы вирусологии
Introduction. Altai Krai is a region with an unfavorable situation of HIV-1 and HCV infection, as well as HIV-1 and HCV coinfection. Due to this, it is necessary to study the HCV genetic variants and their drug resistance (DR) to direct-acting antivirals
Ilya A. Lapovok, Arina V. Syrkina, Alina A. Kirichenko, Anastasia V. Shlykova, Natalya V. Lukyanenko, Tatyana V. Safyanova, Arina E. Safronova, Valery V. Shevchenko, Dmitry E. Kireev   +8 more
doaj   +1 more source

Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China

Frontiers in Microbiology, 2019
Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral agents (DAAs) targeting hepatitis C virus (HCV) and lead to treatment failure.
Jie Lu, Yupeng Feng, Lichang Chen, Zhengyu Zeng, Xianliang Liu, Wei Cai, Hui Wang, Xiaolei Guo, Huijuan Zhou, Wanyin Tao, Qing Xie   +10 more
doaj   +1 more source

HCV NS5A protein containing potential ligands for both Src homology 2 and 3 domains enhances autophosphorylation of Src family kinase Fyn in B cells.

PLoS ONE, 2012
Hepatitis C virus (HCV) infects B lymphocytes and induces mixed cryoglobulinemia and B cell non-Hodgkin's lymphoma. The molecular mechanism for the pathogenesis of HCV infection-mediated B cell disorders remains obscure. To identify the possible role for
Kenji Nakashima, Kenji Takeuchi, Kazuyasu Chihara, Tomoko Horiguchi, Xuedong Sun, Lin Deng, Ikuo Shoji, Hak Hotta, Kiyonao Sada   +8 more
doaj   +1 more source

Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection

Frontiers in Microbiology, 2021
BackgroundHepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs).
Pooneh Rahimi, Heidar Sharafi, Golnaz Bahramali, FaridehSadat SajadianFard, Nafiseh Sadat Asadi, Seyed Moayed Alavian, Vahid Iranpur Mobarakeh, Seyedeh Zahra Moravej   +7 more
doaj   +1 more source

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Viruses, 2018
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals.
Teresa I. Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Liangjun Lu, Armen Asatryan, Andrew Campbell, Betty Yao, Sandra Lovell, Federico Mensa, Eric J. Lawitz, Jens Kort, Christine Collins   +17 more
doaj   +1 more source

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.

PLoS Pathogens, 2013
The lipid kinase phosphatidylinositol 4-kinase III alpha (PI4KIIIα) is an essential host factor of hepatitis C virus (HCV) replication. PI4KIIIα catalyzes the synthesis of phosphatidylinositol 4-phosphate (PI4P) accumulating in HCV replicating cells due ...
Simon Reiss, Christian Harak, Inés Romero-Brey, Danijela Radujkovic, Rahel Klein, Alessia Ruggieri, Ilka Rebhan, Ralf Bartenschlager, Volker Lohmann   +8 more
doaj   +1 more source

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

Viruses, 2021
About 4% of the population in Taiwan are seropositive for anti-HCV Ab and 70% with HCV RNA. To address this high chronic hepatitis C disease load, Taiwan National Health Insurance started reimbursing genotype-specific DAAs in 2017 and pangenotype DAAs in
Chun-Ming Hong, You-Yu Lin, Chun-Jen Liu, Ya-Yun Lai, Shiou-Hwei Yeh, Hung-Chih Yang, Jia-Horng Kao, Shih-Jer Hsu, Yi-Hsiang Huang, Sheng-Shun Yang, Hsing-Tao Kuo, Pin-Nan Cheng, Ming-Lung Yu, Pei-Jer Chen   +13 more
doaj   +1 more source

eEF1A Interacts with the NS5A Protein and Inhibits the Growth of Classical Swine Fever Virus

Viruses, 2015
The NS5A protein of classical swine fever virus (CSFV) is involved in the RNA synthesis and viral replication. However, the NS5A-interacting cellular proteins engaged in the CSFV replication are poorly defined.
Su Li, Shuo Feng, Jing-Han Wang, Wen-Rui He, Hua-Yang Qin, Hong Dong, Lian-Feng Li, Shao-Xiong Yu, Yongfeng Li, Hua-Ji Qiu   +9 more
doaj   +1 more source